↓ Skip to main content

Aflibercept: a review of its use in the treatment of choroidal neovascularization due to age-related macular degeneration

Overview of attention for article published in Clinical Ophthalmology, December 2015
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (86th percentile)
  • High Attention Score compared to outputs of the same age and source (90th percentile)

Mentioned by

twitter
3 X users
patent
9 patents

Citations

dimensions_citation
47 Dimensions

Readers on

mendeley
82 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Aflibercept: a review of its use in the treatment of choroidal neovascularization due to age-related macular degeneration
Published in
Clinical Ophthalmology, December 2015
DOI 10.2147/opth.s80040
Pubmed ID
Authors

Chandrakumar Balaratnasingam, Elona Dhrami-Gavazi, Jesse T McCann, Quraish Ghadiali, K Bailey Freund

Abstract

Choroidal neovascularization (CNV) due to age-related macular degeneration (AMD) is an important cause of visual morbidity globally. Modern treatment strategies for neovascular AMD achieve regression of CNV by suppressing the activity of key growth factors that mediate angiogenesis. Vascular endothelial growth factor (VEGF) has been the major target of neovascular AMD therapy for almost two decades, and there have been several intravitreally-administered agents that have enabled anatomical restitution and improvement in visual function with continual dosing. Aflibercept (EYLEA(®)), initially named VEGF Trap-eye, is the most recent anti-VEGF agent to be granted US Food and Drug Administration approval for the treatment of neovascular AMD. Biologic advantages of aflibercept include its greater binding affinity for VEGF, a longer intravitreal half-life relative to other anti-VEGF agents, and the capacity to antagonize growth factors other than VEGF. This paper provides an up-to-date summary of the molecular mechanisms mediating CNV. The structural, pharmacodynamic, and pharmacokinetic advantages of aflibercept are also reviewed to rationalize the utility of this agent for treating CNV. Results of landmark clinical investigations, including VIEW 1 and 2 trials, and other important studies are then summarized and used to illustrate the efficacy of aflibercept for managing treatment-naïve CNV, recalcitrant CNV, and CNV due to polypoidal choroidal vasculopathy. Safety profile, patient tolerability, and quality of life measures related to aflibercept are also provided. The evidence provided in this paper suggests aflibercept to be a promising agent that can be used to reduce the treatment burden of neovascular AMD.

X Demographics

X Demographics

The data shown below were collected from the profiles of 3 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 82 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
United States 1 1%
Unknown 81 99%

Demographic breakdown

Readers by professional status Count As %
Student > Ph. D. Student 14 17%
Student > Bachelor 13 16%
Student > Master 8 10%
Researcher 7 9%
Student > Doctoral Student 6 7%
Other 15 18%
Unknown 19 23%
Readers by discipline Count As %
Medicine and Dentistry 25 30%
Biochemistry, Genetics and Molecular Biology 6 7%
Pharmacology, Toxicology and Pharmaceutical Science 6 7%
Immunology and Microbiology 3 4%
Agricultural and Biological Sciences 2 2%
Other 13 16%
Unknown 27 33%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 11. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 08 November 2023.
All research outputs
#3,275,006
of 25,374,917 outputs
Outputs from Clinical Ophthalmology
#235
of 3,714 outputs
Outputs of similar age
#51,549
of 395,418 outputs
Outputs of similar age from Clinical Ophthalmology
#7
of 70 outputs
Altmetric has tracked 25,374,917 research outputs across all sources so far. Compared to these this one has done well and is in the 86th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 3,714 research outputs from this source. They receive a mean Attention Score of 4.9. This one has done particularly well, scoring higher than 93% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 395,418 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 86% of its contemporaries.
We're also able to compare this research output to 70 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 90% of its contemporaries.